107 results on '"Creed, T"'
Search Results
2. Activating STING1-dependent immune signaling inTP53mutant and wild-type acute myeloid leukemia
- Author
-
Kogan, Aksinija A., primary, Topper, Michael J., additional, Dellomo, Anna J., additional, Stojanovic, Lora, additional, McLaughlin, Lena J., additional, Creed, T. Michael, additional, Eberly, Christian L., additional, Kingsbury, Tami J., additional, Baer, Maria R., additional, Kessler, Michael D., additional, Baylin, Stephen B., additional, and Rassool, Feyruz V., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease
- Author
-
Kriel, M. H., Tobias, J. H., Creed, T. J., Lockett, M., Linehan, J., Bell, A., Przemioslo, R., Smithson, J. E., Brooklyn, T. N., Fraser, W. D., and Probert, C. S. J.
- Published
- 2010
- Full Text
- View/download PDF
4. OC-004 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants
- Author
-
Heap, GA, Singh, A, Bewshea, C, Weedon, MN, Cole, A, Creed, T, Greig, E, Irving, P, Lindsay, J, Mawdsley, J, Mazhar, Z, Orchard, T, Reffitt, D, Holden, A, and Ahmad, T
- Published
- 2014
- Full Text
- View/download PDF
5. Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
- Author
-
Kogan, Aksinija A., Topper, Michael J., Dellomo, Anna J., Stojanovic, Lora, McLaughlin, Lena J., Creed, T. Michael, Eberly, Christian L., Kingsbury, Tami J., Baer, Maria R., Kessler, Michael D., Baylin, Stephen B., and Rassool, Feyruz V.
- Subjects
ACUTE myeloid leukemia ,POLY ADP ribose ,FIREPROOFING agents ,ENDOGENOUS retroviruses ,CANCER genes ,GENETIC counseling - Abstract
DNA methyltransferase inhibitors (DNMTis) reexpress hypermethylated genes in cancers and leukemias and also activate endogenous retroviruses (ERVs), leading to interferon (IFN) signaling, in a process known as viral mimicry. In the present study we show that in the subset of acute myeloid leukemias (AMLs) with mutations in TP53, associated with poor prognosis, DNMTis, important drugs for treatment of AML, enable expression of ERVs and IFN and inflammasome signaling in a STING-dependent manner. We previously reported that in solid tumors poly ADP ribose polymerase inhibitors (PARPis) combined with DNMTis to induce an IFN/inflammasome response that is dependent on STING1 and is mechanistically linked to generation of a homologous recombination defect (HRD). We now show that STING1 activity is actually increased in TP53 mutant compared with wild-type (WT) TP53 AML. Moreover, in TP53 mutant AML, STING1-dependent IFN/inflammatory signaling is increased by DNMTi treatment, whereas in AMLs with WT TP53, DNMTis alone have no effect. While combining DNMTis with PARPis increases IFN/inflammatory gene expression in WT TP53 AML cells, signaling induced in TP53 mutant AML is still several-fold higher. Notably, induction of HRD in both TP53 mutant and WT AMLs follows the pattern of STING1-dependent IFN and inflammatory signaling that we have observed with drug treatments. These findings increase our understanding of the mechanisms that underlie DNMTi + PARPi treatment, and also DNMTi combinations with immune therapies, suggesting a personalized approach that statifies by TP53 status, for use of such therapies, including potential immune activation of STING1 in AML and other cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2
- Author
-
Parkes, G, primary, Akbar, A, additional, Beales, I, additional, Buckley, M, additional, Creed, T, additional, Din, S, additional, Fraser, A, additional, Plevris, N, additional, Meadowcroft, S, additional, Owen, G, additional, and Heggs, N, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Pulse cyclophosphamide in steroid-resistant inflammatory bowel disease: authorsʼ reply
- Author
-
CREED, T. J. and PROBERT, C.
- Published
- 2007
8. Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies
- Author
-
CREED, T. J. and PROBERT, C. S. J.
- Published
- 2007
9. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
- Author
-
Probert, CSJ, Sebastian, S, Gaya, DR, Hamlin, PJ, Gillespie, G, Rose, A, Tate, H, Wheeler, C, Irving, PM, Probert, C, Gaya, D, Hart, A, Irving, P, Ahmad, T, Pollok, R, Orchard, T, Arasaradnam, R, Iqbal, T, Johnson, M, Kaser, A, Allen, P, Gordon, J, Preston, C, Shenderey, R, Hoque, S, Bloom, S, Ansari, A, Mowat, C, Hamlin, J, Arnott, I, Shaw, I, Steed, H, Butterworth, J, Robinson, A, Mawdsley, J, Creed, T, Cummings, F, and GO-COLITIS Study Grp
- Abstract
Objective GO-COLITIS aimed to measure the effectiveness of subcutaneous golimumab in tumour necrosis factor-α antagonist–naive patients with moderate to severe ulcerative colitis (UC) despite conventional treatment.\ud \ud Design GO-COLITIS was an open label, single arm, phase 4 study with a pragmatic design which reflected UK clinical practice. Adult patients were eligible if diagnosed with UC ≥3 months, partial Mayo score (PMS) 4–9. Patients received subcutaneous golimumab induction (200 mg initially and 100 mg at week 2) followed at week 6 by 50 mg or 100 mg (depending on weight) every 4 weeks until week 54 with a 12-week follow-up. Efficacy was measured by PMS at baseline, week 6, 30, 54 and 66. Health-related quality of life (HRQoL; Inflammatory Bowel Disease Questionnaire (IBDQ) and EuroQol Group 5 Dimensions Health Questionnaire (EQ-5D)) was assessed at baseline, week 6 and week 54. All safety adverse events (AEs) were recorded.\ud \ud Results 207 patients were enrolled and 205 received golimumab (full analysis set (FAS)205). At week 6, 68.8% (95% CI 62.0% to 75.1%) and 38.5% (95% CI 31.8% to 45.6%) of patients were in response and remission, respectively, using PMS. At the end of the induction phase, 140/141 patients in clinical response continued into the maintenance phase (Maintenance FAS). Sustained clinical response through week 54 was achieved in 51/205 (24.9%) of the FAS205 population and 51/140 (36.4%) of the Maintenance FAS population. Statistically significant improvements from baseline to week 6 were observed for the IBDQ total score and for each IBDQ domain score (bowel symptoms, emotional function, systemic symptoms and social function), as well as the EQ-5D index score and associated visual analogue scale score (p
- Published
- 2018
10. Should we monitor vitamin B12 levels in patients who have had end-ileostomy for inflammatory bowel disease?
- Author
-
Jayaprakash, A., Creed, T., Stewart, L., Colton, B., Mountford, R., Standen, G., and Probert, C.
- Published
- 2004
- Full Text
- View/download PDF
11. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease
- Author
-
CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., and DAYAN, C. M.
- Published
- 2006
12. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis
- Author
-
CREED, T. J., NORMAN, M. R., PROBERT, C. S. J., HARVEY, R. F., SHAW, I. S., SMITHSON, J., ANDERSON, J., MOORGHEN, M., GUPTA, J., SHEPHERD, N. A., DAYAN, C. M., and HEARING, S. D.
- Published
- 2003
13. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
- Author
-
Mowat, C, Arnott, I, Cahill, A, Smith, M, Ahmad, T, Subramanian, S, Travis, S, Morris, J, Hamlin, J, Dhar, A, Nwokolo, C, Edwards, C, Creed, T, Bloom, S, Yousif, M, Thomas, L, Campbell, S, Lewis, SJ, Sebastian, S, Sen, S, Lal, S, Hawkey, C, Murray, C, Cummings, F, Goh, J, Lindsay, JO, Arebi, N, Potts, L, McKinley, AJ, Thomson, JM, Todd, JA, Collie, M, Dunlop, MG, Mowat, A, Gaya, DR, Winter, J, Naismith, GD, Ennis, H, Keerie, C, Lewis, S, Prescott, RJ, Kennedy, NA, Satsangi, J, and TOPPIC Study Group
- Abstract
BACKGROUND: Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease. METHODS: We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of patients (aged >16 years in Scotland or >18 years in England and Wales) who had a confirmed diagnosis of Crohn's disease and had undergone intestinal resection. Patients were randomly assigned (1:1) by a computer-generated web-based randomisation system to oral daily mercaptopurine at a dose of 1 mg/kg bodyweight rounded to the nearest 25 mg or placebo; patients with low thiopurine methyltransferase activity received half the normal dose. Patients and their carers and physicians were masked to the treatment allocation. Patients were followed up for 3 years. The primary endpoint was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plus 100-point increase in score) and the need for anti-inflammatory rescue treatment or primary surgical intervention. Primary and safety analyses were by intention to treat. Subgroup analyses by smoking status, previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or age at diagnosis were also done. This trial is registered with the International Standard Randomised Controlled Trial Register (ISRCTN89489788) and the European Clinical Trials Database (EudraCT number 2006-005800-15). FINDINGS: Between June 6, 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to mercaptopurine and 112 to placebo. All patients received at least one dose of study drug, and no randomly assigned patients were excluded from the analysis. 16 (13%) of patients in the mercaptopurine group versus 26 (23%) patients in the placebo group had a clinical recurrence of Crohn's disease and needed anti-inflammatory rescue treatment or primary surgical intervention (adjusted hazard ratio [HR] 0·54, 95% CI 0·27-1·06; p=0·07; unadjusted HR 0·53, 95% CI 0·28-0·99; p=0·046). In a subgroup analysis, three (10%) of 29 smokers in the mercaptopurine group and 12 (46%) of 26 in the placebo group had a clinical recurrence that needed treatment (HR 0·13, 95% CI 0·04-0·46), compared with 13 (13%) of 99 non-smokers in the mercaptopurine group and 14 (16%) of 86 in the placebo group (0·90, 0·42-1·94; pinteraction=0·018). The effect of mercaptopurine did not significantly differ from placebo for any of the other planned subgroup analyses (previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or age at diagnosis). The incidence and types of adverse events were similar in the mercaptopurine and placebo groups. One patient on placebo died of ischaemic heart disease. Adverse events caused discontinuation of treatment in 39 (30%) of 128 patients in the mercaptopurine group versus 41 (37%) of 112 in the placebo group. INTERPRETATION: Mercaptopurine is effective in preventing postoperative clinical recurrence of Crohn's disease, but only in patients who are smokers. Thus, in smokers, thiopurine treatment seems to be justified in the postoperative period, although smoking cessation should be strongly encouraged given that smoking increases the risk of recurrence.
- Published
- 2017
14. HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
- Author
-
Heap, Ga, Weedon, Mn, Bewshea, Cm, Singh, A, Chen, M, Satchwell, Jb, Vivian, Jp, So, K, Dubois, Pc, Andrews, Jm, Annese, V, Bampton, P, Barnardo, M, Bell, S, Cole, A, Connor, Sj, Creed, T, Cummings, Fr, D'Amato, M, Daneshmend, Tk, Fedorak, Rn, Florin, Th, Gaya, Dr, Greig, E, Halfvarson, J, Hart, A, Irving, Pm, Jones, G, Karban, A, Lawrance, Ic, Lee, Jc, Lees, C, Lev Tzion, R, Lindsay, Jo, Mansfield, J, Mawdsley, J, Mazhar, Z, Parkes, M, Parnell, K, Orchard, Tr, Radford Smith, G, Russell, Rk, Reffitt, D, Satsangi, J, Silverberg, Ms, Sturniolo, Giacomo, Tremelling, M, Tsianos, Ev, van Heel DA, Walsh, A, Watermeyer, G, Weersma, Rk, Zeissig, S, Rossjohn, J, Holden, Al, Ahmad, T, International Serious Adverse Events Consortium, IBD Pharmacogenetics Study Group, and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Subjects
Models, Molecular ,Genotype ,Population ,Genome-wide association study ,Azathioprine ,THERAPY ,Polymorphism, Single Nucleotide ,HLA-DQ alpha-Chains ,Article ,Gene Frequency ,Risk Factors ,Genetics ,medicine ,Humans ,Genetic Predisposition to Disease ,GENOME-WIDE ASSOCIATION ,education ,HLA-DRB1 ,HYPERSENSITIVITY ,POPULATION ,education.field_of_study ,Molecular Structure ,Thiopurine methyltransferase ,biology ,Mercaptopurine ,COMPLICATION ,Odds ratio ,Inflammatory Bowel Diseases ,medicine.disease ,CROHNS-DISEASE ,Protein Structure, Tertiary ,Haplotypes ,Pancreatitis ,INFLAMMATORY-BOWEL-DISEASE, GENOME-WIDE ASSOCIATION, CROHNS-DISEASE, THERAPY, HYPERSENSITIVITY, AZATHIOPRINE, COMPLICATION, POPULATION, GENOTYPE ,Immunology ,biology.protein ,Immunosuppressive Agents ,INFLAMMATORY-BOWEL-DISEASE ,Genome-Wide Association Study ,HLA-DRB1 Chains ,Protein Binding ,medicine.drug - Abstract
Pancreatitis occurs in approximately 4% of patients treated with the thiopurines azathioprine or mercaptopurine. Its development is unpredictable and almost always leads to drug withdrawal. We identified patients with inflammatory bowel disease (IBD) who had developed pancreatitis within 3 months of starting these drugs from 168 sites around the world. After detailed case adjudication, we performed a genome-wide association study on 172 cases and 2,035 controls with IBD. We identified strong evidence of association within the class II HLA region, with the most significant association identified at rs2647087 (odds ratio 2.59, 95% confidence interval 2.07-3.26, P = 2 x 10(-16)). We replicated these findings in an independent set of 78 cases and 472 controls with IBD matched for drug exposure. Fine mapping of the H LA region identified association with the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype. Patients heterozygous at rs2647087 have a 9% risk of developing pancreatitis after administration of a thiopurine, whereas homozygotes have a 17% risk.
- Published
- 2014
15. The PAX-SIX-EYA-DACH network modulates GATA-FOG function in fly hematopoiesis and human erythropoiesis.
- Author
-
Creed, T. Michael, Baldeosingh, Rajkumar, Eberly, Christian L., Schlee, Caroline S., MinJung Kim, Cutler, Jevon A., Pandey, Akhilesh, Civin, Curt I., Fossett, Nancy G., and Kingsbury, Tami J.
- Subjects
- *
HEMATOPOIESIS , *ERYTHROPOIESIS , *GATA proteins , *GENE regulatory networks , *FLIES , *GENE expression , *ERYTHROPOIETIN receptors - Abstract
The GATA and PAX-SIX-EYA-DACH transcriptional networks (PSEDNs) are essential for proper development across taxa. Here, we demonstrate novel PSEDN roles in vivo in Drosophila hematopoiesis and in human erythropoiesis in vitro. Using Drosophila genetics, we show that PSEDN members function with GATA to block lamellocyte differentiation and maintain the prohemocyte pool. Overexpression of human SIX1 stimulated erythroid differentiation of human erythroleukemia TF1 cells and primary hematopoietic stem-progenitor cells. Conversely, SIX1 knockout impaired erythropoiesis in both cell types. SIX1 stimulation of erythropoiesis required GATA1, as SIX1 overexpression failed to drive erythroid phenotypes and gene expression patterns in GATA1 knockout cells. SIX1 can associate with GATA1 and stimulate GATA1- mediated gene transcription, suggesting that SIX1-GATA1 physical interactions contribute to the observed functional interactions. In addition, both fly and human SIX proteins regulated GATA protein levels. Collectively, our findings demonstrate that SIX proteins enhance GATA function at multiple levels, and reveal evolutionarily conserved cooperation between the GATA and PSEDN networks that may regulate developmental processes beyond hematopoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Neutrophil exocytosis induces podocyte cytoskeletal reorganization and proteinuria in experimental glomerulonephritis
- Author
-
Caster, Dawn J., primary, Korte, Erik A., additional, Tan, Min, additional, Barati, Michelle T., additional, Tandon, Shweta, additional, Creed, T. Michael, additional, Salant, David J., additional, Hata, Jessica L., additional, Epstein, Paul N., additional, Huang, Hui, additional, Powell, David W., additional, and McLeish, Kenneth R., additional
- Published
- 2018
- Full Text
- View/download PDF
17. Reports Of Societies
- Author
-
West, Charles, Hewitt, Graily, Sanders, William, Patterson, Alexander, Coats, Joseph, Heath, Frederick A., Gamges, Sampson, Ogston, Francis, Robinson, M. K., Manser, F., Colles, William, Hamilton, Edward, and Creed, T.
- Published
- 1878
18. Model for Forecasting Transportation-Related Wetland Impacts
- Author
-
Piovan, Silvia, Hodgson, M. E., Xu, H., Kupfer, J., Long, C., and Creed, T.
- Subjects
transportation ,mitigation ,model ,LiDAR ,wetlands, model, LiDAR, mitigation, transportation, GIS ,GIS ,wetlands - Published
- 2016
19. Ustekinumab as induction and maintenance therapy for Crohn's disease
- Author
-
Feagan, Bg, Sandborn, Wj, Gasink, C, Jacobstein, D, Lang, Y, Friedman, Jr, Blank, Ma, Johanns, J, Gao, Ll, Miao, Y, Adedokun, Oj, Sands, Be, Hanauer, Sb, Vermeire, S, Targan, S, Ghosh, S, de Villiers WJ, Colombel, Jf, Tulassay, Z, Seidler, U, Salzberg, Ba, Desreumaux, P, Lee, Sd, Loftus EV Jr, Dieleman, La, Katz, S, Rutgeerts, P, Bampton, P, Chung, A, Connor, S, Debinski, H, Leong, R, Macrae, F, Pavli, P, Sorrentino, D, van den Bogaerde, J, Vogel, W, Vogelsang, H, Louis, E, Mana, F, Zaltman, C, Aumais, G, Bernstein, C, Bressler, B, Dhalla, S, Dieleman, L, Feagan, B, Marshall, J, Panaccione, R, Ropeleski, M, Stehlik, J, Volfova, M, Brynskov, J, Glerup, H, Abitbol-Selinger, V, Allez, M, Beaugerie, L, Bourreille, A, Cadiot, G, Dupas, J, Grimaud, J, Laharie, D, Lerebours, E, Moreau, J, Baumgart, D, Brand, S, Ebert, M, Ehehalt, R, Hasselblatt, P, Howaldt, S, Klaus, J, Krummenerl, P, Kucharzik, T, Lügering, A, Mudter, J, Preiss, J, Schreiber, S, Stallmach, A, Stein, J, Strauch, U, Salamon, A, Patchett, S, Lahat-Zok, A, Rachmilewitz, D, Annese, V, Bossa, F, Guidi, L, Kohn, A, Rocca, R, Ando, A, Ashida, T, Hanai, H, Ishida, T, Ito, H, Matsumoto, T, Motoya, S, Nakamura, S, Sameshima, Y, Suzuki, Y, Watanabe, K, Yamagami, H, Yamamoto, T, Yao, K, Kim, H, Kim, Y, D'Haens, G, Pierik, M, van Bodegraven, A, van der Woude CJ, Gearry, R, Ciecko-Michalska, I, Malecka-Panas, E, Jojic, N, Aboo, N, Wright, J, Arranz, M, Viso, L, Ahmad, T, Bloom, S, Campbell, S, Creed, T, Cummings, F, Hawthorne, B, Iqbal, T, Ireland, A, Parkes, M, Pollok, R, Shaw, I, Shonde, A, Smith, M, Steel, A, Subramanian, S, Travis, S, Tremelling, M, Aberra, F, Abraham, B, Barish, C, Behm, B, Birbara, C, Bochner, R, Bologna, S, Brant, S, Charles, R, Cohen, N, de Villers, W, Dryden, G, Duvall, A, Flasar, M, Fleisher, M, Florez, D, Fogel, R, Gagneja, H, Gross, C, Hamilton, J, Hanauer, S, Hanson, J, Hardi, R, Higgins, P, Isaacs, K, Katz, J, Kaur, N, Khan, N, Lee, S, Leman, B, Levenson, S, Lichtiger, S, Loftus, E, Malik, P, Mcnair, A, Melmed, G, Miner, P, Nichols, M, Noar, M, Oikonomou, I, Oubre, B, Peterson, K, Pruitt, R, Quirk, D, Safdi, A, Safdi, M, Salzberg, B, Sandborn, W, Saubermann, L, Scherl, E, Schwartz, D, Schwarz, R, Sedghi, S, Selby, L, Shafran, I, Siegel, C, Sninsky, C, Stern, M, Stockwell, D, Stone, C, Swaminath, A, Swoger, J, Taormina, M, Williams, E, Winstead, N, Wolf, D, Wolosin, J, Yacyshyn, B, Yajnik, V, Yen, E, Hetzel, D, Muls, V, Bafutto, M, Francesconi, C, Sipahi, A, Steinwurz, F, Churchev, J, Kotzev, I, Marinova, I, Penchev, P, Spassova, Z, Stoinov, S, Takov, D, Vassileva, G, Fowler, S, Greenberg, G, Jones, J, Saibil, F, Salh, B, Banić, M, Duvnjak, M, Stimac, D, Goujon, G, Pelletier, A, Peyrin-Biroulet, L, Aldinger, V, Bokemeyer, B, Büning, C, Konturek, J, Krummenerl, T, Ochsenkuehn, T, Altorjay, I, Kis, J, Pecsi, G, Székely, A, Varga, M, Vincze, A, Wacha, J, Oddsson, E, Orvar, K, Avni-Biron, I, Fishman, S, Fraser, G, Konikoff, F, Melzer, E, Oren, R, Shirin, H, Danese, S, Marino, M, Sturniolo, Gc, Horiki, N, Iijima, H, Iwabuchi, M, Kanai, T, Kunisaki, R, Maemoto, A, Matsuoka, K, Osada, T, Sugimoto, K, Tanaka, S, Cheon, Jh, Han, Ds, Jang, Bi, Kim, Hj, Kim, Js, Kim, Yh, Park, Sj, Yang, Sk, Arnold, M, Claydon, A, Haines, M, Hill, J, Rowbotham, D, Schultz, M, Wallace, I, Bochenek, A, Niezgoda, K, Szura, M, Arutyunov, G, Baranovsky, A, Khalif, I, Osipenko, M, Milinic, N, Bloch, H, Kruger, Fc, Prins, M, Watermeyer, G, Ziady, C, Calvo, Xc, Domínguez-Muñoz, Je, Gisbert, Jp, Arsenescu, R, Beaulieu, D, Bedford, R, Behrend, C, Cleavinger, P, Cohen, J, Ertan, A, Freilich, B, Friedenberg, K, Glover, S, Gordon, G, Gunaratnam, N, Gupta, N, Holbrook, R, Jones, M, Kaufman, B, Khan, Nh, Khurana, S, Legnani, P, Mutlu, E, Phillips, R, Rai, R, Reichelderfer, M, Ritter, T, Safdi, Ma, Sands, B, Schulman, M, Smith, J, Suiter, D, Taylor, D, Vasudeva, R, Winstead, T, Zwick, A, Savoye, G, Atreya, R, Ochsenkuhn, T, Ott, C, Goldin, E, Motohiro, E, Takanori, K, Park, S, James, B, Cummings, J, Tariq, A, Willert, R, Allan, M, Bulat, R, Devilliers, W, Eaker, E, Hou, J, Mendu, S, Nicols, M, Proctor, D, Thosani, N, Zhang, C, and UNITI-IM-UNITI Study Group
- Subjects
030203 arthritis & rheumatology ,Adult ,Male ,Infusions ,Medicine (all) ,Remission Induction ,Crohn Disease ,Female ,Humans ,Induction Chemotherapy ,Infusions, Intravenous ,Maintenance Chemotherapy ,Middle Aged ,Ustekinumab ,General Medicine ,Orvostudományok ,Klinikai orvostudományok ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Intravenous - Abstract
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of ≥100 points or a CDAI score150). The primary end point for the maintenance trial was remission at week 44 (CDAI score150).The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P=0.005 and P=0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups.Among patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329 , NCT01369342 , and NCT01369355 .).
- Published
- 2016
20. PWE-056 Single centre experience of vedolizumab in the management of moderate to severe ulcerative colitis and crohn’s disease
- Author
-
Hodges, P, primary, Fraser, A, additional, Gale, T, additional, Dixon, S, additional, Carver, J, additional, Tidley, J, additional, and Creed, T, additional
- Published
- 2017
- Full Text
- View/download PDF
21. Frontline Science: Tumor necrosis factor-α stimulation and priming of human neutrophil granule exocytosis
- Author
-
McLeish, Kenneth R, primary, Merchant, Michael L, additional, Creed, T Michael, additional, Tandon, Shweta, additional, Barati, Michelle T, additional, Uriarte, Silvia M, additional, and Ward, Richard A, additional
- Published
- 2017
- Full Text
- View/download PDF
22. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
- Author
-
Heap, G.A., So, K., Weedon, M., Edney, N., Bewshea, C., Singh, A., Annese, V., Beckly, J., Buurman, D., Chaudhary, R., Cole, A.T., Cooper, S.C., Creed, T., Cummings, F., de Boer, N.K., D'Inca, R., D'Souza, R., Daneshmend, T.K., Delaney, M., Dhar, A., Direkze, N., Dunckley, P., Gaya, D.R., Gearry, R., Gore, S., Halfvarson, J., Hart, A., Hawkey, C.J., Hoentjen, F., Iqbal, T., Irving, P., Lal, S., Lawrence, I., Lees, C.W., Lockett, M., Mann, S., Mansfield, J., Mowat, C., Mulgrew, C.J., Muller, F., Murray, C., Oram, R., Orchard, T., Parkes, M., Phillips, R., Pollok, R., Radford-Smith, G., Sebastian, S., Sen, S., Shirazi, T., Silverberg, M., Solomon, L., Sturniolo, G.C., Thomas, M., Tremelling, M., Tsianos, E.V., Watts, D., Weaver, S., Weersma, R.K., Wesley, E., Holden, A., Ahmad, T., Heap, G.A., So, K., Weedon, M., Edney, N., Bewshea, C., Singh, A., Annese, V., Beckly, J., Buurman, D., Chaudhary, R., Cole, A.T., Cooper, S.C., Creed, T., Cummings, F., de Boer, N.K., D'Inca, R., D'Souza, R., Daneshmend, T.K., Delaney, M., Dhar, A., Direkze, N., Dunckley, P., Gaya, D.R., Gearry, R., Gore, S., Halfvarson, J., Hart, A., Hawkey, C.J., Hoentjen, F., Iqbal, T., Irving, P., Lal, S., Lawrence, I., Lees, C.W., Lockett, M., Mann, S., Mansfield, J., Mowat, C., Mulgrew, C.J., Muller, F., Murray, C., Oram, R., Orchard, T., Parkes, M., Phillips, R., Pollok, R., Radford-Smith, G., Sebastian, S., Sen, S., Shirazi, T., Silverberg, M., Solomon, L., Sturniolo, G.C., Thomas, M., Tremelling, M., Tsianos, E.V., Watts, D., Weaver, S., Weersma, R.K., Wesley, E., Holden, A., and Ahmad, T.
- Abstract
Item does not contain fulltext, BACKGROUND AND AIMS: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically useful genetic markers so that these drugs can be avoided or so that monitoring can be intensified in high-risk patients. METHODS: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion criteria included normal renal function prior to commencing 5-ASA, >/=50% rise in creatinine any time after starting 5-ASA, and physician opinion implicating 5-ASA strong enough to justify drug withdrawal. An adjudication panel identified definite and probable cases from structured case report forms. A genome-wide association study was then undertaken with these cases and 4109 disease controls. RESULTS: After adjudication, 151 cases of 5-ASA-induced nephrotoxicity were identified. Sixty-eight percent of cases were males, with nephrotoxicity occurring at a median age of 39.4 years (range 6-79 years). The median time for development of renal injury after commencing 5-ASA was 3.0 years (95% confidence interval [CI] 2.3-3.7). Only 30% of cases recovered completely after drug withdrawal, with 15 patients requiring permanent renal replacement therapy. A genome-wide association study identified a suggestive association in the HLA region (p = 1x10(-7)) with 5-ASA-induced nephrotoxicity. A sub-group analysis of patients who had a renal biopsy demonstrating interstitial nephritis (n = 55) significantly strengthened this association (p = 4x10(-9), odds ratio 3.1). CONCLUSIONS: This is the largest and most detailed study of 5-ASA-induced nephrotoxicity to date. It highlights the morbidity associated with this condition and identifies for the first time a significant genetic predisposition to drug-induced renal injury.
- Published
- 2016
23. Radiation-induced erectile dysfunction: Recent advances and future directions
- Author
-
Mahmood, Javed, primary, Shamah, Aksinija A., additional, Creed, T. Michael, additional, Pavlovic, Radmila, additional, Matsui, Hotaka, additional, Kimura, Masaki, additional, Molitoris, Jason, additional, Shukla, Hem, additional, Jackson, Isabel, additional, and Vujaskovic, Zeljko, additional
- Published
- 2016
- Full Text
- View/download PDF
24. Neutrophil exocytosis induces podocyte cytoskeletal reorganization and proteinuria in experimental glomerulonephritis.
- Author
-
Caster, Dawn J., Korte, Erik A., Min Tan, Barati, Michelle T., Tandon, Shweta, Michael Creed, T., Salant, X David J., Hata, Jessica L., Epstein, Paul N., Hui Huang, Powell, David W., and McLeish, Kenneth R.
- Abstract
Acute glomerulonephritis is characterized by rapid glomerular neutrophil recruitment, proteinuria, and glomerular hypercellularity. The current study tested the hypothesis that the release of neutrophil granule contents plays a role in both the loss of filtration barrier leading to proteinuria and the increase in glomerular cells. Inhibition of neutrophil exocytosis with a peptide inhibitor prevented proteinuria and attenuated podocyte and endothelial cell injury but had no effect on glomerular hypercellularity in an experimental acute glomerulonephritis model in mice. Cultivation of podocytes with neutrophil granule contents disrupted cytoskeletal organization, an in vitro model for podocyte effacement and loss of filtration barrier. Activated, cultured podocytes released cytokines that stimulated neutrophil chemotaxis, primed respiratory burst activity, and stimulated neutrophil exocytosis. We conclude that crosstalk between podocytes and neutrophils contributes to disruption of the glomerular filtration barrier in acute glomerulonephritis. Neutrophil granule products induce podocyte injury but do not participate in the proliferative response of intrinsic glomerular cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Glycolytic enzymes localize to ribonucleoprotein granules in Drosophila germ cells, bind Tudor and protect from transposable elements
- Author
-
Gao, Ming, primary, Thomson, Travis C, additional, Creed, T Michael, additional, Tu, Shikui, additional, Loganathan, Sudan N, additional, Jackson, Christina A, additional, McCluskey, Patrick, additional, Lin, Yanyan, additional, Collier, Scott E, additional, Weng, Zhiping, additional, Lasko, Paul, additional, Ohi, Melanie D, additional, and Arkov, Alexey L, additional
- Published
- 2015
- Full Text
- View/download PDF
26. Biologics in ulcerative colitis
- Author
-
Creed, T. J., primary and Probert, C. S. J., additional
- Full Text
- View/download PDF
27. P138 The prevalence of vitamin D deficiency in adult patients with Crohn's disease on anti-TNF alpha therapy: report from a large UK teaching hospital
- Author
-
Woodland, H., primary, Arthurs, E., additional, Fraser, A., additional, Tyrrell-Price, J., additional, and Creed, T., additional
- Published
- 2013
- Full Text
- View/download PDF
28. Frontline Science: Tumor necrosis factor-a stimulation and priming of human neutrophil granule exocytosis
- Author
-
McLeish, Kenneth R., Merchant, Michael L., Creed, T. Michael, Tandon, Shweta, Barati, Michelle T., Uriarte, Silvia M., and Ward, Richard A.
- Abstract
TNF-a stimulates exocytosis of secretory vesicles and gelatinase granules, and primes specific and azurophilic granule exocytosis that depend on p38 MAPK and actin reorganization. Neutrophil granule exocytosis plays an important role in innate and adaptive immune responses. The present study examined TNF-a stimulation or priming of exocytosis of the 4 neutrophil granule subsets. TNF-a stimulated exocytosis of secretory vesicles and gelatinase granules and primed specific and azurophilic granule exocytosis to fMLF stimulation. Both stimulation and priming of exocytosis by TNF-a were dependent on p38 MAPK activity. Bioinformatic analysis of 1115 neutrophil proteins identified by mass spectrometry as being phosphorylated by TNF-a exposure found that actin cytoskeleton regulation was a major biologic function. A role for p38 MAPK regulation of the actin cytoskeleton was confirmed experimentally. Thirteen phosphoproteins regulated secretory vesicle quantity, formation, or release, 4 of which—Raf1, myristoylated alanine-rich protein kinase C (PKC) substrate (MARCKS), Abelson murine leukemia interactor 1 (ABI1), and myosin VI—were targets of the p38 MAPK pathway. Pharmacologic inhibition of Raf1 reduced stimulated exocytosis of gelatinase granules and priming of specific granule exocytosis. We conclude that differential regulation of exocytosis by TNF-a involves the actin cytoskeleton and is a necessary component for priming of the 2 major neutrophil antimicrobial defense mechanisms: oxygen radical generation and release of toxic granule contents.
- Published
- 2017
- Full Text
- View/download PDF
29. Endoscopy can be avoided in the assessment of ulcerative colitis in clinical trials
- Author
-
Dhanda, A. D., primary, Greenwood, R., additional, Creed, T. J., additional, and Probert, C. S., additional
- Published
- 2011
- Full Text
- View/download PDF
30. Novel role of specific Tudor domains in Tudor–Aubergine protein complex assembly and distribution during Drosophila oogenesis
- Author
-
Michael Creed, T., primary, Loganathan, Sudan N., additional, Varonin, Dan, additional, Jackson, Christina A., additional, and Arkov, Alexey L., additional
- Published
- 2010
- Full Text
- View/download PDF
31. Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment
- Author
-
Parker, R., primary, Dixit, A., additional, Fraser, A., additional, Creed, T. J, additional, and Probert, C. S, additional
- Published
- 2010
- Full Text
- View/download PDF
32. Mortality in ulcerative colitis--what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6 year retrospective case review
- Author
-
Falvey, J, primary, Greenwood, R, additional, Creed, T J, additional, Smithson, J, additional, Sylvester, P, additional, Fraser, A, additional, and Probert, C S, additional
- Published
- 2010
- Full Text
- View/download PDF
33. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease
- Author
-
Kriel, M. H., primary, Tobias, J. H., additional, Creed, T. J., additional, Lockett, M., additional, Linehan, J., additional, Bell, A., additional, Przemioslo, R., additional, Smithson, J. E., additional, Brooklyn, T. N., additional, Fraser, W. D., additional, and Probert, C. S. J., additional
- Published
- 2009
- Full Text
- View/download PDF
34. Should we monitor vitamin B 12 levels in patients who have had end-ileostomy for inflammatory bowel disease?
- Author
-
Jayaprakash, A., primary, Creed, T., additional, Stewart, L., additional, Colton, B., additional, Mountford, R., additional, Standen, G., additional, and Probert, C., additional
- Published
- 2004
- Full Text
- View/download PDF
35. Should we monitor vitamin B12 levels in patients who have had end-ileostomy for inflammatory bowel disease?
- Author
-
Jayaprakash, A., Creed, T., Stewart, L., Colton, B., Mountford, R., Standen, G., and Probert, C.
- Subjects
- *
VITAMIN B12 , *ILEOSTOMY , *ILEUM surgery , *INFLAMMATORY bowel diseases , *PATIENTS - Abstract
Background and aims. We examined whether vitamin B12 levels are low following surgery in those patients who have had end-ileostomy for inflammatory bowel disease. Patients and methods. This prospective observational study used the database of a university teaching hospital to identify patients with inflammatory bowel disease with an end-ileostomy constructed more than 30 months previously. Precise diagnosis, disease distribution and details of their surgery were collected from case notes of the 39 eligible patients (18 Crohn’s disease, 17 ulcerative colitis, 4 indeterminate colitis). Mean duration since ileostomy formation was 12.53 years. Patients found to be vitamin B12 deficient underwent further investigations to ascertain the cause of their vitamin B12 deficiency (<150 ng/l). Results. There was no significant difference between serum vitamin B12 levels in patients with Crohn’s disease and those in patients with ulcerative colitis following end ileostomy formation. Two patients (5.1%) were identified as having vitamin B12 deficiency. One of these had had a panproctocolectomy for Crohn’s disease, followed by subsequent resection for ileal obstruction and ongoing small intestinal disease. The other had had colectomy for ulcerative colitis, in whom no cause other than the ileostomy was found for the vitamin B12 deficiency. There was no significant correlation between serum vitamin B12 levels and duration of ileostomy overall or in the disease subgroups. Conclusion. We do not recommend routine screening for vitamin B12 deficiency in this group of patients unless they have undergone additional small bowel resection or have ongoing small bowel inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
36. PWE-056 Single centre experience of vedolizumab in the management of moderate to severe ulcerative colitis and crohn’s disease
- Author
-
Hodges, P, Fraser, A, Gale, T, Dixon, S, Carver, J, Tidley, J, and Creed, T
- Abstract
IntroductionVedolizumab is recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for adults with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn’s disease (CD) where tumour necrosis factor (TNF) alpha inhibition is either unsuitable or has been ineffective. As the drug was approved by NICE in 2015 there is currently limited available real world data on its clinical effectiveness. We report outcomes of vedolizumab use in a group of 23 patients at a single UK centre.MethodDiagnosis is recorded in the table below with UC patients subcategorised according to disease location.DiagnosisNumber of patients%Crohn’s disease 2 8.7 Ulcerative colitis 21 91.3 Pan colitis628.6Left sided disease628.6Rectosigmoid523.8Extent of disease unclear419.030.4% of patients (n=7/23) were documented to have already received at least 1 biologic agent prior to starting vedolizumab and 13% of patients (n=3/23) had received 2 or more biological agents prior to starting vedolizumab. Patients received infusions of 300 mg vedolizumab at weeks 0, 2, 6, then at 8 weekly intervals thereafter. Patient reported outcomes were recorded at each visit for drug infusion using the Modified Mayo Score (MMS) for patients with UC and the Harvey Bradshaw index (HBI) for patients with CD. Biochemical markers of disease activity were measured at each visit and a faecal calprotectin measurement at 16 weeks post treatment commencement. A clinical review at 16 weeks and at 1 year was also recorded.ResultsA reduction in MMS or HBI was noted in 43.5% of all patients (n=10/23) at 14 weeks. A reduction of ≥50% was noted in 38.1% of UC patients (n=8/21) at 14 weeks. At 30 weeks, 60% had a MMS of 0 (n=6/10). MMS is documented in 3 patients at 52 weeks. Of these, 2 showed a reduction from baseline of more than 60%. 1 patient did not have a recorded baseline MMS hence comparison was not possible. A reduction in HBI was recorded in both patients with CD at 14 weeks. This was a reduction of 16.7% in one patient and 82.4% in the other. All faecal calprotectin measurements done prior to commencing vedolizumab were elevated. 21.7% of patients (n=5/23) had a faecal calprotectin within the normal range 14 weeks after commencing treatment. Of the 5 patients who have completed 1 year of treatment, 40% are in clinical remission and continue on vedolizumab infusions every 8 weeks. Drug administration was recorded on 139 occasions. Adverse reaction was noted on a single occasion (0.01%) which was documented as “arm felt heavy post infusion”.ConclusionPatient reported outcomes showed a combined response rate of 43.5% (n=10/23) at 14 weeks in CD and UC. This is comparable to published trial data.Disclosure of InterestNone Declared
- Published
- 2017
- Full Text
- View/download PDF
37. DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML
- Author
-
Kogan, Aksinija A, Mclaughlin, Lena J, Topper, Michael, Muvarak, Nidal, Stojanovic, Lora, Creed, T Michael, Bentzen, Soren, Civin, Curt I., Baer, Maria R., Kingsbury, Tami J, Baylin, Stephen, and Rassool, Feyruz V.
- Abstract
Poly (ADP-ribose) polymerase inhibitors (PARPis) have shown clinical efficacy in breast and ovarian cancers with inherited mutations in BRCA genes that abrogate homologous recombination (HR) DNA double-strand break (DSB) repair activity. However, to date, PARPishave not had success in sporadic breast and ovarian cancers, or other cancers, such as acute myeloid leukemia (AML), with intact BRCA genes. We have recently reported that triple-negative breast cancer (TNBC) and AML are sensitive to low doses of the potent PARPiTalazoparib in combination with DNA methyl transferase inhibitors (DNMTi), decitabine (DAC) or azacitidine (AZA), in vitro and in vivo. In these cancer models, the DNMTi/PARPicombination increases amplitude and retention of PARP1 directly at laser-induced DNA damage sites, increasing DNA DSBs, promoting synergistic tumor cytotoxicity, blunting cell self-renewal, and leading to strong anti-tumor responses. These results have led to a Phase I/II Clinical trial of DNMTi/PARPi combination therapy in patients with relapsed/refractory AML that is underway.
- Published
- 2017
- Full Text
- View/download PDF
38. Development, validation, and utility of Internet-based, behavioral health screen for adolescents.
- Author
-
Diamond G, Levy S, Bevans KB, Fein JA, Wintersteen MB, Tien A, and Creed T
- Published
- 2010
- Full Text
- View/download PDF
39. BRECKINRIDGE CO., Kentucky, April 22, 1863.
- Author
-
MEADOR, CREED T.
- Published
- 1863
40. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
- Author
-
Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier P Gisbert, Geert D'Haens, Bu'hussain Hayee, Remo Panaccione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber, Nazimuddin Aboo, Tariq Ahmad, Xavier Aldeguer Mante, Matthieu Allez, Sven Almer, Romain Altwegg, Montserrat Andreu Garcia, Ramesh Arasaradnam, Sandro Ardizzone, Alessandro Armuzzi, Ian Arnott, Guy Aumais, Irit Avni-Biron, Peter Barrow, Ian Beales, Fernando Bermejo San Jose, Abraham Bezuidenhout, Livia Biancone, Michael Blaeker, Stuart Bloom, Bernd Bokemeyer, Fabrizio Bossa, Peter Bossuyt, Guillaume Bouguen, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Arnaud Bourreille, Christian Boustiere, Tomas Brabec, Stephan Brand, Carsten Buening, Anthony Buisson, Guillaume Cadiot, Xavier Calvet Calvo, Franck Carbonnel, Daniel Carpio, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Nicoleta-Claudia Cimpoeru, Martin Clodi, Gino Roberto Corazza, Rocco Cosintino, Jose Cotter, Thomas Creed, Fraser Cummings, Gian Luigi de' Angelis, Marc De Maeyer, Milind Desai, Etienne Desilets, Pierre Desreumaux, Olivier Dewit, Johanna Dinter, Ecaterina Daniela Dobru, Tomas Douda, Dan Lucian Dumitrascu, Matthias Ebert, Ana Echarri Piudo, Magdy Elkhashab, Chang Soo Eun, Brian Feagan, Roland Fejes, Catarina Fidalgo, Sigal Fishman, Bernard Flourié, Sharyle Fowler, Walter Fries, Csaba Fulop, Mathurin Fumery, Gyula G Kiss, Sonja Gassner, Daniel Gaya, Bastianello Germanà, Liliana Simona Gheorghe, Cyrielle Gilletta de Saint Joseph, Paolo Gionchetti, Adrian-Eugen Goldis, Raquel Gonçalves, Jean-Charles Grimaud, Tibor Gyökeres, Herve Hagege, Andrei Haidar, Heinz Hartmann, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Per Hellström, Pieter Hindryckx, Helena Hlavova, Frank Hoentjen, Stefanie Howaldt, Ludek Hrdlicka, Kyu Chan Huh, Maria Isabel Iborra Colomino, Florentina Ionita-Radu, Peter Irving, Jørgen Jahnsen, ByungIk Jang, Jeroen Jansen, Seong Woo Jeon, Rodrigo Jover Martinez, Pascal Juillerat, Per Karlén, Arthur Kaser, Radan Keil, Deepak Kejariwal, Dan Keret, Reena Khanna, Dongwoo Kim, Duk Hwan Kim, Hyo-Jong Kim, Joo Sung Kim, Kueongok Kim, Kyung-Jo Kim, Sung Kook Kim, Young-Ho Kim, Jochen Klaus, Anna Kohn, Vladimir Kojecky, Ja Seol Koo, Robert Kozak, Milan Kremer, Tunde Kristof, Frederik Kruger, David Laharie, Adi Lahat-zok, Evgeny Landa, Jonghun Lee, Kang-Moon Lee, Kook Lae Lee, YooJin Lee, Frank Lenze, Wee Chian Lim, Jimmy Limdi, James Lindsay, Pilar Lopez Serrano, Edouard Louis, Stefan Lueth, Giovanni Maconi, Fazia Mana, Steven Mann, John Mansfield, Santino Marchi, Marco Marino, John Marshall, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, John McLaughlin, Simon McLaughlin, Ehud Melzer, Jessica Mertens, Paul Mitrut, Tamas Molnar, Vinciane Muls, Pushpakaran Munuswamy, Charles Murray, Timna Naftali, Visvakuren Naidoo, Yusuf Nanabhay, Lucian Negreanu, Augustin Nguyen, Thomas Ochsenkuehn, Ambrogio Orlando, Julian Panes Diaz, Maya Paritsky, Dong Il Park, Jihye Park, Luca Pastorelli, Markus Peck-Radosavljevic, Farhad Peerani, Javier Perez Gisbert, Laurent Peyrin-Biroulet, Laurence Picon, Marieke Pierik, Terry Ponich, Francisco Portela, Maartens Jeroen Prins, Istvan Racz, Khan Fareed Rahman, Jean-Marie Reimund, Max Reinshagen, Xavier Roblin, Rodolfo Rocca, Francesca Rogai, Gerhard Rogler, Agnes Salamon, Ennaliza Salazar, Zoltan Sallo, Sunil Samuel, Miquel de los Santos Sans Cuffi, Edoardo Vincenzo Savarino, Vincenzo Savarino, Guillaume Savoye, Andrada Seicean, Christian Selinger, David Martins Serra, Hang Hock Shim, SungJae Shin, Britta Siegmund, Jesse Siffledeen, Wayne Simmonds, Jan Smid, Jose Sollano, Geun Am Song, Alexander Speight, Ioan Sporea, Dirk Staessen, George Stancu, Alan Steel, David Stepek, Victor Stoica, Andreas Sturm, Gyorgy Szekely, Teck Kiang Tan, Carlos Taxonera Samso, John Thomson, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Marcello Vangeli, Marta Varga, Ana Vieira, Stephanie Viennot, Erica Villa, Petr Vitek, Harald Vogelsang, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Byong Duk Ye, Christopher Ziady, Danese S., Colombel J.-F., Lukas M., Gisbert J.P., D'Haens G., Hayee B., Panaccione R., Kim H.-S., Reinisch W., Tyrrell H., Oh Y.S., Tole S., Chai A., Chamberlain-James K., Tang M.T., Schreiber S., Aboo N., Ahmad T., Aldeguer Mante X., Allez M., Almer S., Altwegg R., Andreu Garcia M., Arasaradnam R., Ardizzone S., Armuzzi A., Arnott I., Aumais G., Avni-Biron I., Barrow P., Beales I., Bermejo San Jose F., Bezuidenhout A., Biancone L., Blaeker M., Bloom S., Bokemeyer B., Bossa F., Bossuyt P., Bouguen G., Bouhnik Y., Bouma G., Bourdages R., Bourreille A., Boustiere C., Brabec T., Brand S., Buening C., Buisson A., Cadiot G., Calvet Calvo X., Carbonnel F., Carpio D., Cheon J.H., Chiba N., Chioncel C., Cimpoeru N.-C., Clodi M., Corazza G.R., Cosintino R., Cotter J., Creed T., Cummings F., de' Angelis G.L., De Maeyer M., Desai M., Desilets E., Desreumaux P., Dewit O., Dinter J., Dobru E.D., Douda T., Dumitrascu D.L., Ebert M., Echarri Piudo A., Elkhashab M., Eun C.S., Feagan B., Fejes R., Fidalgo C., Fishman S., Flourie B., Fowler S., Fries W., Fulop C., Fumery M., G Kiss G., Gassner S., Gaya D., Germana B., Gheorghe L.S., Gilletta de Saint Joseph C., Gionchetti P., Goldis A.-E., Goncalves R., Grimaud J.-C., Gyokeres T., Hagege H., Haidar A., Hartmann H., Hasselblatt P., Hebuterne X., Hellstrom P., Hindryckx P., Hlavova H., Hoentjen F., Howaldt S., Hrdlicka L., Huh K.C., Iborra Colomino M.I., Ionita-Radu F., Irving P., Jahnsen J., Jang B., Jansen J., Jeon S.W., Jover Martinez R., Juillerat P., Karlen P., Kaser A., Keil R., Kejariwal D., Keret D., Khanna R., Kim D., Kim D.H., Kim H.-J., Kim J.S., Kim K., Kim K.-J., Kim S.K., Kim Y.-H., Klaus J., Kohn A., Kojecky V., Koo J.S., Kozak R., Kremer M., Kristof T., Kruger F., Laharie D., Lahat-zok A., Landa E., Lee J., Lee K.-M., Lee K.L., Lee Y., Lenze F., Lim W.C., Limdi J., Lindsay J., Lopez Serrano P., Louis E., Lueth S., Maconi G., Mana F., Mann S., Mansfield J., Marchi S., Marino M., Marshall J., Martin Arranz M.D., Mateescu R.-B., McLaughlin J., McLaughlin S., Melzer E., Mertens J., Mitrut P., Molnar T., Muls V., Munuswamy P., Murray C., Naftali T., Naidoo V., Nanabhay Y., Negreanu L., Nguyen A., Ochsenkuehn T., Orlando A., Panes Diaz J., Paritsky M., Park D.I., Park J., Pastorelli L., Peck-Radosavljevic M., Peerani F., Perez Gisbert J., Peyrin-Biroulet L., Picon L., Pierik M., Ponich T., Portela F., Prins M.J., Racz I., Rahman K.F., Reimund J.-M., Reinshagen M., Roblin X., Rocca R., Rogai F., Rogler G., Salamon A., Salazar E., Sallo Z., Samuel S., Sans Cuffi M.D.L.S., Savarino E.V., Savarino V., Savoye G., Seicean A., Selinger C., Serra D.M., Shim H.H., Shin S., Siegmund B., Siffledeen J., Simmonds W., Smid J., Sollano J., Song G.A., Speight A., Sporea I., Staessen D., Stancu G., Steel A., Stepek D., Stoica V., Sturm A., Szekely G., Tan T.K., Taxonera Samso C., Thomson J., Tichy M., Toth G.T., Tulassay Z., Vangeli M., Varga M., Vieira A., Viennot S., Villa E., Vitek P., Vogelsang H., Vyhnalek P., Wahab P., Walldorf J., Ye B.D., and Ziady C.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Population ,Antibodies, Monoclonal, Humanized ,Injections, Subcutaneou ,Placebo ,Severity of Illness Index ,Gastroenterology ,Young Adult ,Double-Blind Method ,Internal medicine ,Gastrointestinal Agent ,Clinical endpoint ,medicine ,education ,Adverse effect ,Aged ,Aged, 80 and over ,education.field_of_study ,Hepatology ,business.industry ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Infliximab ,Treatment Outcome ,Etrolizumab ,Concomitant ,Colitis, Ulcerative ,Female ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Human ,medicine.drug - Abstract
Item does not contain fulltext BACKGROUND: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to compare the safety and efficacy of etrolizumab with infliximab in patients with moderately to severely active ulcerative colitis. METHODS: We conducted a randomised, double-blind, double-dummy, parallel-group, phase 3 study (GARDENIA) across 114 treatment centres worldwide. We included adults (age 18-80 years) with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6-12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. Patients were required to have had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. Participants were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks or intravenous infliximab 5 mg/kg at 0, 2, and 6 weeks and every 8 weeks thereafter for 52 weeks. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, and baseline disease activity. All participants and study site personnel were masked to treatment assignment. The primary endpoint was the proportion of patients who had both clinical response at week 10 (MCS ≥3-point decrease and ≥30% reduction from baseline, plus ≥1-point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) and clinical remission at week 54 (MCS ≤2, with individual subscores ≤1); efficacy was analysed using a modified intention-to-treat population (all randomised patients who received at least one dose of study drug). GARDENIA was designed to show superiority of etrolizumab over infliximab for the primary endpoint. This trial is registered with ClinicalTrials.gov, NCT02136069, and is now closed to recruitment. FINDINGS: Between Dec 24, 2014, and June 23, 2020, 730 patients were screened for eligibility and 397 were enrolled and randomly assigned to etrolizumab (n=199) or infliximab (n=198). 95 (48%) patients in the etrolizumab group and 103 (52%) in the infliximab group completed the study through week 54. At week 54, 37 (18·6%) of 199 patients in the etrolizumab group and 39 (19·7%) of 198 in the infliximab group met the primary endpoint (adjusted treatment difference -0·9% [95% CI -8·7 to 6·8]; p=0·81). The number of patients reporting one or more adverse events was similar between treatment groups (154 [77%] of 199 in the etrolizumab group and 151 [76%] of 198 in the infliximab group); the most common adverse event in both groups was ulcerative colitis (55 [28%] patients in the etrolizumab group and 43 [22%] in the infliximab group). More patients in the etrolizumab group reported serious adverse events (including serious infections) than did those in the infliximab group (32 [16%] vs 20 [10%]); the most common serious adverse event was ulcerative colitis (12 [6%] and 11 [6%]). There was one death during follow-up, in the infliximab group due to a pulmonary embolism, which was not considered to be related to study treatment. INTERPRETATION: To our knowledge, this trial is the first phase 3 maintenance study in moderately to severely active ulcerative colitis to use infliximab as an active comparator. Although the study did not show statistical superiority for the primary endpoint, etrolizumab performed similarly to infliximab from a clinical viewpoint. FUNDING: F Hoffmann-La Roche.
- Published
- 2022
41. Unveiling errors in soil microbial community sequencing: a case for reference soils and improved diagnostics for nanopore sequencing.
- Author
-
Manter DK, Reardon CL, Ashworth AJ, Ibekwe AM, Lehman RM, Maul JE, Miller DN, Creed T, Ewing PM, Park S, Ducey TF, Tyler HL, Veum KS, Weyers SL, and Knaebel DB
- Subjects
- Reproducibility of Results, Microbiota genetics, Sequence Analysis, DNA methods, Polymerase Chain Reaction methods, Soil chemistry, High-Throughput Nucleotide Sequencing methods, Soil Microbiology, Nanopore Sequencing methods
- Abstract
The sequencing platform and workflow strongly influence microbial community analyses through potential errors at each step. Effective diagnostics and experimental controls are needed to validate data and improve reproducibility. This cross-laboratory study evaluates sources of variability and error at three main steps of a standardized amplicon sequencing workflow (DNA extraction, polymerase chain reaction [PCR], and sequencing) using Oxford Nanopore MinION to analyze agricultural soils and a simple mock community. Variability in sequence results occurs at each step in the workflow with PCR errors and differences in library size greatly influencing diversity estimates. Common bioinformatic diagnostics and the mock community are ineffective at detecting PCR abnormalities. This work outlines several diagnostic checks and techniques to account for sequencing depth and ensure accuracy and reproducibility in soil community analyses. These diagnostics and the inclusion of a reference soil can help ensure data validity and facilitate the comparison of multiple sequencing runs within and between laboratories., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
42. Multi-label Multi-task Deep Learning for Behavioral Coding.
- Author
-
Gibson J, Atkins DC, Creed T, Imel Z, Georgiou P, and Narayanan S
- Abstract
We propose a methodology for estimating human behaviors in psychotherapy sessions using mutli-label and multi-task learning paradigms. We discuss the problem of behavioral coding in which data of human interactions is the annotated with labels to describe relevant human behaviors of interest. We describe two related, yet distinct, corpora consisting of therapist client interactions in psychotherapy sessions. We experimentally compare the proposed learning approaches for estimating behaviors of interest in these datasets. Specifically, we compare single and multiple label learning approaches, single and multiple task learning approaches, and evaluate the performance of these approaches when incorporating turn context. We demonstrate the prediction performance gains which can be achieved by using the proposed paradigms and discuss the insights these models provide into these complex interactions.
- Published
- 2022
- Full Text
- View/download PDF
43. The Structure of Competence: Evaluating the Factor Structure of the Cognitive Therapy Rating Scale.
- Author
-
Goldberg SB, Baldwin SA, Merced K, Caperton DD, Imel ZE, Atkins DC, and Creed T
- Subjects
- Adult, Cognitive Behavioral Therapy methods, Factor Analysis, Statistical, Female, Humans, Male, Psychometrics methods, Reproducibility of Results, Clinical Competence standards, Cognitive Behavioral Therapy standards, Psychometrics standards
- Abstract
The Cognitive Therapy Rating Scale (CTRS) is an observer-rated measure of cognitive behavioral therapy (CBT) treatment fidelity. Although widely used, the factor structure and psychometric properties of the CTRS are not well established. Evaluating the factorial validity of the CTRS may increase its utility for training and fidelity monitoring in clinical practice and research. The current study used multilevel exploratory factor analysis to examine the factor structure of the CTRS in a large sample of therapists (n = 413) and observations (n = 1,264) from community-based CBT training. Examination of model fit and factor loadings suggested that three within-therapist factors and one between-therapist factor provided adequate fit and the most parsimonious and interpretable factor structure. The three within-therapist factors included items related to (a) session structure, (b) CBT-specific skills and techniques, and (c) therapeutic relationship skills, although three items showed some evidence of cross-loading. All items showed moderate to high loadings on the single between-therapist factor. Results support continued use of the CTRS and suggest factors that may be a relevant focus for therapists, trainers, and researchers., (Copyright © 2019. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
44. A Non-randomized Comparison of Strategies for Consultation in a Community-Academic Training Program to Implement an Evidence-Based Psychotherapy.
- Author
-
Stirman SW, Pontoski K, Creed T, Xhezo R, Evans AC, Beck AT, and Crits-Christoph P
- Subjects
- Adult, Female, Humans, Male, Young Adult, Evidence-Based Practice, Psychotherapy education, Referral and Consultation
- Abstract
Despite the central role of training and consultation in the implementation of evidence-based psychological interventions (EBPIs), comprehensive reviews of research on training have highlighted serious gaps in knowledge regarding best practices. Consultation after initial didactic training appears to be of critical importance, but there has been very little research to determine optimal consultation format or interventions. This observational study compared two consultation formats that included review of session audio and feedback in the context of a program to train clinicians (n = 85) in community mental health clinics to deliver cognitive therapy (CT). A "gold standard" condition in which clinicians received individual feedback after expert consultants reviewed full sessions was compared to a group consultation format in which short segments of session audio were reviewed by a group of clinicians and an expert consultant. After adjusting for potential baseline differences between individuals in the two consultation conditions, few differences were found in terms of successful completion of the consultation phase or in terms of competence in CT at the end of consultation or after a 2 year follow-up. However, analyses did not support hypotheses regarding non-inferiority of the group consultation condition. While both groups largely maintained competence, clinicians in the group consultation condition demonstrated increases in competence over the follow-up period, while a sub-group of those in the individual condition experienced decreases. These findings, if replicated, have important implications for EBP implementation programs, as they suggest that observation and feedback is feasible in community mental health setting, and that employing this method in a group format is an effective and efficient consultation strategy that may enhance the implementation and sustainability of evidence-based psychotherapies.
- Published
- 2017
- Full Text
- View/download PDF
45. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
- Author
-
Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J, Hamlin J, Dhar A, Nwokolo C, Edwards C, Creed T, Bloom S, Yousif M, Thomas L, Campbell S, Lewis SJ, Sebastian S, Sen S, Lal S, Hawkey C, Murray C, Cummings F, Goh J, Lindsay JO, Arebi N, Potts L, McKinley AJ, Thomson JM, Todd JA, Collie M, Dunlop MG, Mowat A, Gaya DR, Winter J, Naismith GD, Ennis H, Keerie C, Lewis S, Prescott RJ, Kennedy NA, and Satsangi J
- Subjects
- Administration, Oral, Adolescent, Adult, Aged, Crohn Disease diagnosis, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Smoking adverse effects, Treatment Outcome, Young Adult, Crohn Disease prevention & control, Crohn Disease surgery, Immunosuppressive Agents therapeutic use, Mercaptopurine therapeutic use, Secondary Prevention methods
- Abstract
Background: Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease., Methods: We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospitals of patients (aged >16 years in Scotland or >18 years in England and Wales) who had a confirmed diagnosis of Crohn's disease and had undergone intestinal resection. Patients were randomly assigned (1:1) by a computer-generated web-based randomisation system to oral daily mercaptopurine at a dose of 1 mg/kg bodyweight rounded to the nearest 25 mg or placebo; patients with low thiopurine methyltransferase activity received half the normal dose. Patients and their carers and physicians were masked to the treatment allocation. Patients were followed up for 3 years. The primary endpoint was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plus 100-point increase in score) and the need for anti-inflammatory rescue treatment or primary surgical intervention. Primary and safety analyses were by intention to treat. Subgroup analyses by smoking status, previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or age at diagnosis were also done. This trial is registered with the International Standard Randomised Controlled Trial Register (ISRCTN89489788) and the European Clinical Trials Database (EudraCT number 2006-005800-15)., Findings: Between June 6, 2008, and April 23, 2012, 240 patients with Crohn's disease were randomly assigned: 128 to mercaptopurine and 112 to placebo. All patients received at least one dose of study drug, and no randomly assigned patients were excluded from the analysis. 16 (13%) of patients in the mercaptopurine group versus 26 (23%) patients in the placebo group had a clinical recurrence of Crohn's disease and needed anti-inflammatory rescue treatment or primary surgical intervention (adjusted hazard ratio [HR] 0·54, 95% CI 0·27-1·06; p=0·07; unadjusted HR 0·53, 95% CI 0·28-0·99; p=0·046). In a subgroup analysis, three (10%) of 29 smokers in the mercaptopurine group and 12 (46%) of 26 in the placebo group had a clinical recurrence that needed treatment (HR 0·13, 95% CI 0·04-0·46), compared with 13 (13%) of 99 non-smokers in the mercaptopurine group and 14 (16%) of 86 in the placebo group (0·90, 0·42-1·94; p
interaction =0·018). The effect of mercaptopurine did not significantly differ from placebo for any of the other planned subgroup analyses (previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or age at diagnosis). The incidence and types of adverse events were similar in the mercaptopurine and placebo groups. One patient on placebo died of ischaemic heart disease. Adverse events caused discontinuation of treatment in 39 (30%) of 128 patients in the mercaptopurine group versus 41 (37%) of 112 in the placebo group., Interpretation: Mercaptopurine is effective in preventing postoperative clinical recurrence of Crohn's disease, but only in patients who are smokers. Thus, in smokers, thiopurine treatment seems to be justified in the postoperative period, although smoking cessation should be strongly encouraged given that smoking increases the risk of recurrence., Funding: Medical Research Council., (Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2016
- Full Text
- View/download PDF
46. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
- Author
-
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, Cole AT, Cooper SC, Creed T, Cummings F, de Boer NK, D'Inca R, D'Souza R, Daneshmend TK, Delaney M, Dhar A, Direkze N, Dunckley P, Gaya DR, Gearry R, Gore S, Halfvarson J, Hart A, Hawkey CJ, Hoentjen F, Iqbal T, Irving P, Lal S, Lawrance I, Lees CW, Lockett M, Mann S, Mansfield J, Mowat C, Mulgrew CJ, Muller F, Murray C, Oram R, Orchard T, Parkes M, Phillips R, Pollok R, Radford-Smith G, Sebastian S, Sen S, Shirazi T, Silverberg M, Solomon L, Sturniolo GC, Thomas M, Tremelling M, Tsianos EV, Watts D, Weaver S, Weersma RK, Wesley E, Holden A, and Ahmad T
- Subjects
- Acute Kidney Injury pathology, Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Child, Female, Genotype, HLA Antigens metabolism, Humans, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Kidney drug effects, Male, Mesalamine therapeutic use, Middle Aged, Phenotype, Young Adult, Acute Kidney Injury chemically induced, DNA analysis, Genome-Wide Association Study methods, HLA Antigens genetics, Inflammatory Bowel Diseases drug therapy, Kidney pathology, Mesalamine adverse effects
- Abstract
Background and Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically useful genetic markers so that these drugs can be avoided or so that monitoring can be intensified in high-risk patients., Methods: Inflammatory bowel disease patients were recruited from 89 sites around the world. Inclusion criteria included normal renal function prior to commencing 5-ASA, ≥50% rise in creatinine any time after starting 5-ASA, and physician opinion implicating 5-ASA strong enough to justify drug withdrawal. An adjudication panel identified definite and probable cases from structured case report forms. A genome-wide association study was then undertaken with these cases and 4109 disease controls., Results: After adjudication, 151 cases of 5-ASA-induced nephrotoxicity were identified. Sixty-eight percent of cases were males, with nephrotoxicity occurring at a median age of 39.4 years (range 6-79 years). The median time for development of renal injury after commencing 5-ASA was 3.0 years (95% confidence interval [CI] 2.3-3.7). Only 30% of cases recovered completely after drug withdrawal, with 15 patients requiring permanent renal replacement therapy. A genome-wide association study identified a suggestive association in the HLA region (p = 1×10(-7)) with 5-ASA-induced nephrotoxicity. A sub-group analysis of patients who had a renal biopsy demonstrating interstitial nephritis (n = 55) significantly strengthened this association (p = 4×10(-9), odds ratio 3.1)., Conclusions: This is the largest and most detailed study of 5-ASA-induced nephrotoxicity to date. It highlights the morbidity associated with this condition and identifies for the first time a significant genetic predisposition to drug-induced renal injury., (Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
47. System-Level Influences on the Sustainability of a Cognitive Therapy Program in a Community Behavioral Health Network.
- Author
-
Stirman SW, Matza A, Gamarra J, Toder K, Xhezo R, Evans AC, Hurford M, Beck AT, Crits-Christoph P, and Creed T
- Subjects
- Cooperative Behavior, Evidence-Based Medicine, Female, Humans, Interviews as Topic, Male, Pennsylvania, Cognitive Behavioral Therapy economics, Community Networks, Health Personnel, Program Evaluation economics
- Abstract
Objective: The purpose of this study was to examine influences on the sustainability of a program to implement an evidence-based psychotherapy in a mental health system., Methods: Interviews with program administrators, training consultants, agency administrators, and supervisors (N=24), along with summaries of program evaluation data and program documentation, were analyzed with a directed content-analytic approach., Results: Findings suggested a number of interconnected and interacting influences on sustainability, including alignment with emerging sociopolitical influences and system and organizational priorities; program-level adaptation and evolution; intervention flexibility; strong communication, collaboration, planning, and support; and perceived benefit. These individual factors appeared to mutually influence one another and contribute to the degree of program sustainability achieved at the system level. Although most influences were positive, financial planning and support emerged as potentially both facilitator and barrier, and evaluation of benefits at the patient level remained a challenge., Conclusions: Several factors appeared to contribute to the sustainability of a psychosocial intervention in a large urban mental health system and warrant further investigation. Understanding interconnections between multiple individual facilitators and barriers appears critical to advancing understanding of sustainability in dynamic systems and adds to emerging recommendations for other implementation efforts. In particular, implications of the findings include the importance of implementation strategies, such as long-term planning, coalition building, clarifying roles and expectations, planned adaptation, evaluation, diversification of financing strategies, and incentivizing implementation.
- Published
- 2015
- Full Text
- View/download PDF
48. Sexual trauma history does not moderate treatment outcome in Attachment-Based Family Therapy (ABFT) for adolescents with suicide ideation.
- Author
-
Diamond G, Creed T, Gillham J, Gallop R, and Hamilton JL
- Subjects
- Adolescent, Female, Humans, Male, Psychiatric Status Rating Scales, Rape psychology, Suicide, Attempted prevention & control, Suicide, Attempted psychology, Treatment Outcome, Child Abuse, Sexual psychology, Family Therapy, Suicidal Ideation
- Abstract
Despite the well-documented association between history of sexual trauma (HSA) and suicide ideation, HSA is largely overlooked in suicide treatment studies. Existing studies showed that patients with a HSA have a weaker treatment response. In this randomized clinical trial for suicide ideation, HSA did not moderate treatment outcome for Attachment-Based Family Therapy (ABFT). Adolescents responded better to ABFT than a control condition, regardless of HSA status. At baseline, adolescents with HSA were also more likely to report past suicide attempts than those without HSA, indicating that they are a particularly important subgroup to consider when developing and evaluating interventions that target suicide ideation. Findings suggest that ABFT is a robust intervention for suicide ideation regardless of HSA., (PsycINFO Database Record (c) 2012 APA, all rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
49. Novel role of specific Tudor domains in Tudor-Aubergine protein complex assembly and distribution during Drosophila oogenesis.
- Author
-
Creed TM, Loganathan SN, Varonin D, Jackson CA, and Arkov AL
- Subjects
- Animals, Drosophila Proteins genetics, Drosophila melanogaster metabolism, Female, Membrane Transport Proteins genetics, Mutation, Peptide Initiation Factors genetics, Protein Interaction Domains and Motifs, Drosophila Proteins metabolism, Drosophila melanogaster physiology, Membrane Transport Proteins metabolism, Oogenesis, Peptide Initiation Factors metabolism
- Abstract
Germ cells give rise to the next generation and contain ribonucleoprotein particles, germ granules. In these granules, Piwi protein Aubergine has been shown to interact with Tudor protein in Drosophila. Tudor protein has 11 Tudor domains and it has been unclear to what extent all these domains are involved in the interaction with Aubergine. Here we present direct biochemical evidence that Tudor-Aubergine interaction surface is composed of different Tudor domains including those that have not been previously implicated in Aubergine recognition. Furthermore, we show that specific single Tudor domains determine localization of Tudor complex to different sites in ovarian germ cells. Our data suggest that multiple Tudor domains of germline proteins from various species are redundantly used for interaction with the same protein partner during germline development., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
50. Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome.
- Author
-
Christmas DM, Badawy AA, Hince D, Davies SJ, Probert C, Creed T, Smithson J, Afzal M, Nutt DJ, and Potokar JP
- Subjects
- Adult, Affect, Amino Acids, Neutral blood, Case-Control Studies, Dairy Products, Female, Humans, Irritable Bowel Syndrome psychology, Kynurenine blood, Male, Middle Aged, Oxidation-Reduction, Tryptophan administration & dosage, Diarrhea blood, Diet, Irritable Bowel Syndrome blood, Serotonin metabolism, Tryptophan blood, Tryptophan Oxygenase blood
- Abstract
Irregularities of serotonin function in irritable bowel syndrome (IBS) may be due to changes in the metabolism of the serotonin precursor l-tryptophan. Dietary alteration of tryptophan intake may impact upon the mood and bowel symptoms of IBS. We hypothesized that diarrhea-predominant irritable bowel syndrome (d-IBS) patients would exhibit an increase in plasma tryptophan due to alterations in tryptophan metabolism. We also hypothesized that a diet low in tryptophan would reverse this change and reduce symptoms. Thirteen patients with d-IBS had fasting serum free and total tryptophan, large neutral amino acids, and 6 kynurenine metabolites measured before and after 2 weeks of a strict dairy-free diet. Baseline tryptophan parameters were compared with an age- and sex-matched control group. Changes in the specific tryptophan parameters before and after dairy-free diet were correlated with symptoms of IBS and mood. Compared with the control group, d-IBS patients at baseline exhibited significantly higher free serum tryptophan (10.5 ± 4.35 vs 4.75 ± 2.43 μmol/L [means ± standard deviation], P = .006) and significantly lower tryptophan dioxygenase and total tryptophan oxidation as measured by the kynurenine to free tryptophan and total kynurenines to free tryptophan ratios (23.37 ± 10.12 vs 55.33 ± 16.02, P < .001 and 49.34 ± 17.84 vs 258.46 ± 98.67, P < .001, respectively). Dairy-free diet did not modulate metabolites of the kynurenine pathway or symptoms. Tryptophan metabolism along the kynurenine pathway is inhibited in d-IBS, and a dairy-free diet does not alter this. Our findings are consistent with possible enhanced serotonin activity in d-IBS., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.